- Pfizer Inc (NYSE:PFE) has dosed the first participants in the Phase 3 trial of its quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults.
- Influenza annually causes 140,000 to 710,000 hospitalizations, 12,000 to 52,000 deaths, and about $25 billion in economic loss in the U.S.
- The quadrivalent modRNA vaccine candidate will encode World Health Organization recommended strains for the Northern Hemisphere 2022-23 cell culture- or recombinant-based influenza vaccines.
- This Phase 3 study is informed by previously shared data from the ongoing Phase 2 trial, demonstrating a safety and immunogenicity profile supportive of program advancement.
- Beyond the modRNA vaccine candidate, Pfizer has ongoing studies exploring more novel mRNA technology like self-amplifying RNA (saRNA).
- In 2018, Pfizer entered into a worldwide collaboration and license agreement with BioNTech SE (NASDAQ: BNTX), under which Pfizer has the exclusive right to carry out the clinical development and commercialization of mRNAâ€based influenza vaccines.
- BioNTech would receive a royalty on Pfizer’s sales upon potential approval and commercialization.
- Price Action: PFE shares are down 0.13% at $46.13 during the premarket session on the last check Wednesday.
Hillstream BioPharma Licenses Technology To Develop Proprietary HER2 And HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, And Ovarian Cancers
Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective against a number of epithelial tumors
Antibody CDRs
